UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000004300
Receipt number R000005140
Scientific Title Anti-Hypertensive treatment of Nephrosclerosis in Elderly
Date of disclosure of the study information 2010/10/01
Last modified on 2016/10/04 17:23:15

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Anti-Hypertensive treatment of Nephrosclerosis in Elderly

Acronym

Anti-Hypertensive treatment of Nephrosclerosis in Elderly

Scientific Title

Anti-Hypertensive treatment of Nephrosclerosis in Elderly

Scientific Title:Acronym

Anti-Hypertensive treatment of Nephrosclerosis in Elderly

Region

Japan


Condition

Condition

Nephrosclerosis

Classification by specialty

Medicine in general Nephrology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To compare reno-protective effects of olmesaltan with or without azelnidipine in nephroscrelosis patients.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1

Exploratory

Trial characteristics_2

Explanatory

Developmental phase

Phase IV


Assessment

Primary outcomes

Change of estimated GFR before and after the treatment

Key secondary outcomes

Change of following paparemters before and after the treatment
(1) 1/serum creatinine concetration
(2) Office blood pressure
(3) heart rate
(4) urinary albumin excretion
(5) serum concentrations of BUN, cystatin C, and hs-CRP.


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Open -no one is blinded

Control

Active

Stratification

NO

Dynamic allocation

YES

Institution consideration

Institution is considered as adjustment factor in dynamic allocation.

Blocking

YES

Concealment

Central registration


Intervention

No. of arms

2

Purpose of intervention

Treatment

Type of intervention

Medicine

Interventions/Control_1

After observation period for 4 weeks with 20mg of olmesartan, participants were randomly assigned to a group treated with 40mg of olmesartan for 52 weeks.

Interventions/Control_2

After observation period for 4 weeks with 20mg of olmesartan, participants were randomly assigned to a group treated with 20mg of olmesartan plus 16mg of azelnidipine for 52 weeks.

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

65 years-old <=

Age-upper limit

80 years-old >

Gender

Male and Female

Key inclusion criteria

(1) Participants who gave written informed consent.
(2) Outpatients
(3)Systolic blood pressure at clinic is more than 140 mmHg or diastolic pressure is more than 90 mmHg
(4)Serum HbA1c concentration is less than 6.0
(5)urinary albumin excretion is less than 1g/g.Cr.
(6)Patients treated with RAS-inhibitor but not with Ca channel blocker for 2 months just before initiation of the study.

Key exclusion criteria

1. Hypertensive crisis
2. Hyperkalemia (serum potassium conc.>5.5mM)
3. renal failure (eGFR<30ml/min/1.73m2)
4. bilateral renal artery stenosis
5. newly onset of stroke (within 6 months just before entry)
6. severe congestive heart failure (more than NYHA class III)
7. liver dysfunction (AST/ALT concentration is 5 fold higher than normal range)
8. newly onset of acute myocardial infarction.
9. Malignancy
10. Patients who had severe adverse reactions by Ca channel blockers of RAS inhibitors.
11. Patients who are prescribed immunosuppressant or glucocorticoids.
12. Patients who are prescribed NSAIDs for long time (more than 2 weeks).
13. Patients whose doctors determined as inadequate for the study.

Target sample size

100


Research contact person

Name of lead principal investigator

1st name
Middle name
Last name Kunihiro Yamagata

Organization

University of Tsukuba

Division name

Nephrology

Zip code


Address

1-1-1 Tennodai, Tsukuba, Ibaraki, Japan

TEL

029-853-3202

Email

k-yamaga@md.tsukuba.ac.jp


Public contact

Name of contact person

1st name
Middle name
Last name Chie Saito

Organization

University of Tsukuba

Division name

Nephrology

Zip code


Address

1-1-1 Tennodai, Tsukuba, Ibaraki, Japan

TEL

029-853-3202

Homepage URL


Email

chie.saito@md.tsukuba.ac.jp


Sponsor or person

Institute

Department of Nephrology, University of Tsukuba.

Institute

Department

Personal name



Funding Source

Organization

Department of Nephrology, University of Tsukuba.

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

japan


Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization


Address


Tel


Email



Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

1. いなしきクリニック(茨城県)
2. 医療法人 桜雄会 塚田整形外科(茨城県)
3. 医療法人社団 光栄会 田谷医院(茨城県)        
4. 医療法人 慈厚会 野上病院(茨城県)
5. 医療法人 道淑会 高野医院(茨城県)
6. 医療法人社団 厚真会 ごとう内科(茨城県)
7. 医療法人社団 桜井内科医院(茨城県)
8. 医療法人社団 三輪会 山手医院(茨城県)
9. かしむら内科消化器科クリニック(茨城県)
10. 医療法人新岳会 研究学園クリニック(茨城県)
11. なかの循環器クリニック(茨城県)
12. なるしま内科医院(茨城県)
13. 南大通りクリニック (茨城県)
14. 宮﨑クリニック(茨城県)
15. やまぐち医院(茨城県)
16. いとう内科胃腸科医院(茨城県)
17. 中島医科歯科クリニック(茨城県)
18. 医療法人社団 しば医院(茨城県)
19. 海老原医院(茨城県)
20. 桜橋クリニック(茨城県)
21. 筑波大学附属病院(茨城県)


Other administrative information

Date of disclosure of the study information

2010 Year 10 Month 01 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2010 Year 07 Month 28 Day

Date of IRB


Anticipated trial start date

2010 Year 09 Month 01 Day

Last follow-up date

2013 Year 12 Month 31 Day

Date of closure to data entry

2014 Year 01 Month 31 Day

Date trial data considered complete

2014 Year 01 Month 31 Day

Date analysis concluded

2014 Year 03 Month 31 Day


Other

Other related information



Management information

Registered date

2010 Year 09 Month 30 Day

Last modified on

2016 Year 10 Month 04 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000005140


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name